本页面由Tiger Trade Technology Pte. Ltd.提供服务

Zenas BioPharma Inc.

20.16
+0.61003.12%
成交量:98.46万
成交额:1,949.89万
市值:12.57亿
市盈率:-2.39
高:20.41
开:20.38
低:19.27
收:19.55
52周最高:44.60
52周最低:6.11
股本:6,237.10万
流通股本:3,984.16万
量比:1.13
换手率:2.47%
股息:- -
股息率:- -
每股收益(TTM):-8.4400
每股收益(LYR):-8.4448
净资产收益率:-136.22%
总资产收益率:-35.06%
市净率:5.19
市盈率(LYR):-2.39

数据加载中...

2025/06/04

重要事件披露

Form 8-K - Current report
2025/05/15

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/05/15

重要事件披露

Form 8-K - Current report
2025/03/11

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/03/11

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/05

重要事件披露

Form 8-K - Current report
2024/12/03

重要事件披露

Form 8-K - Current report
2024/11/12

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/11/12

重要事件披露

Form 8-K - Current report
2024/10/21

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/09/25

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/09/23

超过5%披露

Form SC 13D - General Statement of Acquisition of Beneficial Ownership
2024/09/23

超过5%披露

Form SC 13D - General Statement of Acquisition of Beneficial Ownership
2024/09/23

超过5%披露

Form SC 13D - General Statement of Acquisition of Beneficial Ownership
2024/09/16

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/09/16

重要事件披露

Form 8-K - Current report
2024/09/11

SEC问询函

Form CORRESP - Correspondence
2024/09/11

SEC问询函

Form CORRESP - Correspondence
2024/09/06

[修订]招股说明书

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2024/08/28

SEC问询函

Form CORRESP - Correspondence